APA (7th ed.) Citation

S, A., M, C., D, C., M, D., DM, S., A, H., . . . L, S. (2024). Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data. Current problems in cancer, 50, 101078. https://doi.org/10.1016/j.currproblcancer.2024.101078

Chicago Style (17th ed.) Citation

S, Ailawadhi, Cheng M, Cherepanov D, DerSarkissian M, Stull DM, Hilts A, Chun J, Duh MS, and Sanchez L. "Comparative Effectiveness of Lenalidomide/dexamethasone-based Triplet Regimens for Treatment of Relapsed And/or Refractory Multiple Myeloma in the United States: An Analysis of Real-world Electronic Health Records Data." Current Problems in Cancer 50 (2024): 101078. https://doi.org/10.1016/j.currproblcancer.2024.101078.

MLA (9th ed.) Citation

S, Ailawadhi, et al. "Comparative Effectiveness of Lenalidomide/dexamethasone-based Triplet Regimens for Treatment of Relapsed And/or Refractory Multiple Myeloma in the United States: An Analysis of Real-world Electronic Health Records Data." Current Problems in Cancer, vol. 50, 2024, p. 101078, https://doi.org/10.1016/j.currproblcancer.2024.101078.